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Phase liB Trial of Aerosolized tgAAVCF for Cystic Fibrosis 
R.B. Moss 1, A.E. Heald 9 and the 25E01 Study Group 
~Stanford University, Palo Alto, CA, United States and 2Targeted Genetics 
Corporatiotg Seattle, WA, United States 
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INS37217 (denufosol tekasodium) inhalation solution: Phase 1 & 2 
clinical experience 
D. Mathews 1, A. Schaberg 1,D. Kellerman 1,L. LaVange 1,J. Engels 1, C. Shaffer 1
~Inspire Plu~rmaceuticals, Inc. USA 
Aims: fi~stic Fibrosis (CF) is a common autosomal recessive disorder in North 
America and Europe. Defective CFTR function in CF airway epithelia can be 
corrected in vitro by inlroducing wild4ype CFTR gene. Recombinant adeno 
associated virus vector encoding the complete human CFTR eDNA (tgAAVCF) has 
been safe and well tolerated ha studies of delivery to the nose, sinus and lungs of CF 
patients. A small (n 37) randomized, ouble blind placebo controlled Phase II trial 
of 3 monthly doses aerosolized tgAAVCF showed positive trends ha pulmonary 
function and induced sputum IL 8 levels (Chest 2(KH;125:509). A larger study was 
thus designed. 
Methods: CF subjects (n 102) with FEV 1 >60% were randomized 1:1 to receive 2 
aerosolized oses of 101~ DNAse resistant particles tgAAVCF or placebo given 30 
days apart. The primary endpoint is 30 day change ha FEV 1. Secondary endpoints 
are change in pulmonary function over time, sputum biomar ker s, days of antibiotic 
use and safety. Safety is reviewed by an independent Data Monitoring Committee 
(DMC) every four months. 
Results: The DMC has not raised any safety concerns and the trial enrolled to target 
goal (n>l(D). Preliminary AE data col~ir m tgAAVCF is safe and well tolerated. 
Conclusion: Active and placebo group results will be presented. 
Funded by Cystic Fibrosis Foundation, NIH/NCRR and Targeted Genetics. 
Aims: INS37217 (INS) is a selective P2Y 2 agonist under development asa treatment 
for CF lung disease. INS enhances cilia beat frequency and mucosal hydration by 
activating CI secretion and illhibiting epithelial Na+ lr maspor t through anon CFTR 
mechmfism in the lung. 
Methods: The tolerability/pharmacological activity of INS is reviewed from 4 
studies (S1 $4) involving 92 healthy volunteers mad 150 mild to moderate CF 
patients. Sl:Non smokers and smokers participated ha an ascending, single dose 
study that evaluated INS doses from 20 320mg vs. placebo (0.9%w/v saline). $2 
S3:CF patients with an FEV 1 >40% of predicted received INS doses of 10 60mg or 
placebo (BID or TID) for 5 28 days. $4: Volunteers received a single dose of INS 
2COmg and blood was collected post dose for PK analysis. All treatments were 
nebulized using the PARI LC Star. 
Results: $1: Non smoking volunteers tolerated the maximum planned dose 
(320mg). Smokers received up to 200mg and demonstrated a ose response increase 
in spontaneous sputum expectoration compared to placebo. $2: CF patients 
receiving doses of 10 60mg with higher lung function appeared to benefit from INS 
more than patients with more severe lung disease, suggesting that INS may be an 
effective arly intervention treatment. This was observed again in the Phase 2 study 
($3: Deterding 2CG4). $4: Little or no systemic absorption was observed following 
dosing with INS 2COmg in volunteers. 
Conclusions: INS is well tolerated ha healthy volunteers. Doses of INS up to 60mg 
are well tolerated ha patients with mild CF lung disease. Systemic absotption of INS 
is minimal after illhalation of a high (2COmg) dose with no apparent systemic 
effects. INS rapidly stimulates expectoration of sputum compared to placebo. 
Inspire plans to initiate a Phase 3 study in 2CO5. 
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Systemic applicated flavonoids ameliorate chloride conductance on 
apical membrane of respiratory epithelia in some patients with cystic 
fibrosis 
D. Schiiler l, K. Weber l, P. Reineck 1, J. Pabst 2, p. Biltner Dersch l, C. Geidel l, C. 
Fegbeutel 1,R. Schulz 1, H. Lindemama 1 
~CF-Centet; Uni~ Giefierg 2puImoTec GmbH, h~Ochstadt/Donau, Germany 
Flavonoids directly applicated on respiratory epithelia are able to ameliorate 
chloride conductance havitro and in vivo ha some patients with cystic fibrosis (CF). 
Undetermined until now is the effect of systemicly applicated flavonoids on apical 
chloride conductance ha respiratory epithelia. 
In 16 CF patients (7 39y.) preponderant with AFSOS/AFS08 nasal potential 
difference (NPD) was measured using superfusion method. After 3 month treated 
with admissioned multicomponent flavonoid preparation (Crataegutt novo ®, 
450mg/d <10y., 9COmg/d >10y.) the NPD measurement was repeated. The study 
was approved by regional ethic committee. 
The basal NPD, the NPD under blocking apical sodium channels and under 
stimulation of altemative Ca ++ dependent chloride channels before and after 
flavonoid treatment was not significantly different. Under stimulation of specific 
CFTR dependent chloride channels a significantly higher repolarisation (P~).01) 
was demonstrable. In 7 CF patients the NPD increases more than 20%. 
So we can conclude that systemicly applicated flavonoids ameliorate CFTR 
dependent chloride conductance on apical membrane of respiratory epithelia ha 
some patients with cystic fibrosis. Further unknown remains the reasons for good or 
bad intestinal absorption of flavonoids. 
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Safety and Efficacy of INS37217 Inhalation Solution in Patient 
Subgroups: Results of a Phase 2 Multicenke Trial 
L L aVange 1,J Engels l, M IQlowles 2, R Deterding 3, D Mathews 1, C Shaffer l 
~Inspire Pharmaceuticals, Inc.; 2Unilz of North Carolina, School of Medicine; 
SChildren's Hospital, Denver CO, USA 
Aims: INS37217 (INS) is a selective P2Y 2 agonist that enhances cilia beat 
frequency and mucosal hydration by activating CI secretion through a non CFFR 
mechmlism ad by inhibiting epithelial Na+ trmlsport. In a recent study (Deterding, 
2(KH), INS was shown to be ffective and well tolerated. The objective of this 
abstract is to report how treatment effects differed by patient characteristics, 
including age, sex, Pa status, baseline FEVI, and concomitmlt therapy. Methods: 
The study was a randomized, double ind, multicentre, 28 day trial of INS (20, 40, 
or 60 rag) versus placebo (0.9% w/v saline) nebulized TID via the PARI LC Star. 
Patients with screening FEV 1 >75% (of predicted normal) without inhaled 
antibiotics were eligible for the study. Subgroup specific treatment effects were 
assessed with respect o change from baseline FEV 1 (mL) adjusted for center mad 
baseline via ANCOVA. Results: 89 patients were randomized and received rug in 
14 centers, and 84 (93%) completed the study. Patients on INS (pooled doses) had 
significantly higher FEV 1 values (p value<0.01) thma patients on placebo at study 
end (A 139 mL; 95% CI [41mL, 237 mL]). Some variation ha treatment effects 
was noted for sex and baseline FEVI, but Pulmozyme use showed the greatest trend. 
Treatment groups were balmaced on pulmozyme use at baseline (53%), mad 
Pulmozyme users appeared to receive greater benefit from INS thma nonusers (A 
190 mL; 95% CI [60 mL, 320 mL] for users vs. A 73 mL; 95% CI [ 71 mL, 
216 mL] for non users). Conclusions: INS appears afe and effective ha a variety 
of patient subgroups, and may have additional benefit among pulmozyme users. A 
Phase 3 study is planned. 
